Pyrazolopyrimidine JAK inhibitor compounds and methods
US8637526B2 · kind B2 · utility
14Cited by
9References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 2, 2011 |
| Grant date | Jan 28, 2014 |
| Priority date | — |
| Expiry date | May 2, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.